{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Bavencio"},{"type":"CodeName","name":"MSB0010718C"},{"type":"Synonym","name":"anti-PD-L1 monoclonal antibody MSB0010718C"},{"type":"CASRegistryName","name":"1537032-82-8"},{"type":"ChemicalStructureName","name":"immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), Homo sapiens monoclonal antibody"},{"type":"CodeName","name":"MSB-0010718C"}],"definition":{"html":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","text":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/avelumab","text":"Avelumab"},"nciConceptId":"C116870","nciConceptName":"Avelumab","termId":745752,"name":"Avelumab","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"avelumab"}],"links":null}